Form 4: Agenus Inc. Insider Stock Transaction

Garo H. Armen, Director and CEO of Agenus Inc., received 4,629 shares of common stock valued at $3.33 per share as salary compensation.

Summary

• Garo H. Armen, who holds positions as Director, CEO, and Principal Financial Officer at Agenus Inc., received 4,629 shares of common stock.
• These shares were issued as compensation for his salary for the pay period ending April 3, 2026, in lieu of cash payment.
• The value of these shares was determined by the closing price of $3.33 on April 2, 2026.
• Following this transaction, Mr. Armen beneficially owns 339,147 shares directly.
• Additionally, he has indirect beneficial ownership of 31,298 shares held in his IRA accounts and 28,950 shares held by the Garo Armen 2020 2 Year AG GRAT, for which he is trustee.
• He also has an interest in 5,000 shares held by Pixie Partners, a General Partnership, though he disclaims beneficial ownership for a portion of these shares due to his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It details a standard insider stock compensation transaction rather than a strategic move or significant financial event.

Positives

• Insider compensation paid in stock can indicate management's confidence in the company's future value.
• The transaction reflects a direct investment of earned compensation into company stock.
• Mr. Armen's total direct and indirect beneficial ownership remains substantial, indicating continued commitment.

Negatives

• The transaction is a salary payment in stock, not an open market purchase, which may not signal strong conviction beyond compensation needs.
• The stock price of $3.33 on April 2, 2026, may be a point of reference for valuation, but the filing does not provide context on whether this is a high or low valuation.

Risks

• The value of the compensation is directly tied to the fluctuating market price of Agenus Inc. common stock.
• Potential for conflicts of interest if compensation structure is not aligned with shareholder interests, though this filing does not provide enough detail to assess this.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. The transaction itself reflects an ongoing compensation practice.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.
• The shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

Industry Context

StockSavvy.ai notes that the use of stock as compensation for executive salaries is a common practice in the biotechnology and pharmaceutical sectors, particularly for companies focused on growth and R&D, where cash conservation may be prioritized. This aligns with Agenus Inc.'s focus on its immuno-oncology pipeline.

Related Party Transactions

• Garo H. Armen's salary compensation paid in stock is a related party transaction, approved by the Compensation Committee.

Stakeholder Impact

• Shareholders: The transaction does not directly dilute existing shareholders as it's a compensation payment. It may be viewed positively if it signals management's commitment and confidence in the company's future value.
• Employees: This practice may set a precedent for other employees or indicate the company's financial strategy regarding cash management.
• Management: Garo H. Armen's compensation is directly tied to the company's stock performance.

Next Steps

• Continued reporting of insider transactions as they occur.
• Monitoring of Agenus Inc.'s stock performance and corporate developments.

Key Dates

Keywords

Agenus Inc., Form 4, Insider Transaction, Stock Compensation, Garo H. Armen, Beneficial Ownership, SEC Filing, Common Stock, Executive Compensation